10 patents
Utility
Humanized anti-CD73 antibodies
2 Jan 24
Provided herein are, inter alia, humanized 1E9 antibodies capable of binding CD73.
Emily Piccione Griffin, Richard A. Miller, Gerhard Johann Frey, Hwai Wen Chang
Filed: 24 Sep 20
Utility
Pharmaceutical formulations
8 Mar 22
The disclosure provides, inter alia, pharmaceutical compositions comprising micronized drug particles of adenosine A2A receptor antagonists, and methods of treating cancer using the pharmaceutical compositions.
Jingrong Xu, William Jones, Felicia Flicker, Bret Berner
Filed: 1 Feb 19
Utility
Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor
22 Feb 22
Zhihong Li, Lubov Konstantinovna Filonova, Erin Kathleen Bradley, Erik Verner
Filed: 31 Aug 18
Utility
Methods of treating cancer
22 Jun 21
Provided herein are, inter alia, methods of treating a cancer tumor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an adenosine A2A receptor antagonist, wherein the subject comprises an elevated level of CD8+ tumor infiltrating lymphocytes relative to a control, the subject comprises an elevated level of T-effector gene signature relative to a control, the subject comprises an increased cancer tumor T cell receptor diversity or blood T cell receptor diversity relative to a control, the cancer tumor comprises an elevated level of PD-L1 relative to a control, and/or the cancer tumor or the blood of the subject comprises an elevated level of CD73 relative to a control.
Andrew Hotson, Richard A. Miller, Ian Mccaffery, Stephen Willingham
Filed: 4 Apr 18
Utility
Compounds and methods for modulating interleukin-2-inducible t-cell kinase
18 May 21
Provided herein, inter alia, are methods and compounds for modulating Interleukin-2-inducible T-cell kinase.
Ryan Hudson, Anne-Marie Beausoleil
Filed: 3 Nov 17
Utility
Methods of treating cancer
9 Feb 21
Provided herein are, inter alia, methods of treating cancer by administering to a subject a therapeutically effective amount of an adenosine-A2A(A2A) receptor antagonist or a combination of an adenosine-A2A(A2A) receptor antagonist and a programmed cell death protein 1(PD-1) signaling pathway inhibitor.
Stephen Willingham, Richard A. Miller, Po Y. Ho, Ian McCaffery, Andrew Hotson
Filed: 22 Dec 16
Utility
Compounds and methods for modulating bruton's tyrosine kinase
21 Dec 20
Provided herein, inter alia, are compounds and methods for modulating Bruton's Tyrosine Kinase.
Ryan Hudson, Anne-Marie Beausoleil, Richard A. Miller, Erik Verner
Filed: 9 Mar 17
Utility
Humanized anti-CD73 antibodies
2 Nov 20
Provided herein are, inter alia, humanized 1E9 antibodies capable of binding CD73.
Emily Piccione Griffin, Richard A. Miller, Gerhard Johann Frey, Hwai Wen Chang
Filed: 8 Dec 16
Utility
Anti-CD73 antibodies
5 Oct 20
Provided herein are, inter alia, anti-CD73 antibodies and methods of using the same.
Emily Piccione Griffin, Richard A. Miller, Ian McCaffery
Filed: 10 Jul 17
Utility
Processes for making triazolo[4,5D] pyramidine derivatives and intermediates thereof
18 May 20
Provided herein are, inter alia, methods for making triazolo[4,5]pyramidine derivatives and intermediates thereof that are useful for treating diseases.
Kolbot By, William Benton Jones, Bradley Hamilton Wolfe
Filed: 29 Mar 18
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first